<DOC>
	<DOCNO>NCT02557412</DOCNO>
	<brief_summary>OBJECTIVES Main objective : To assess six month treatment CPAP , associate conventional treatment , improve lipid profile patient dyslipidemia mild-moderate apnea-hypopnea syndrome ( OSA ) . Secondary objective : - Determine additional effect CPAP insulin resistance dyslipidemia patient mild-moderate OSA . - Assess impact CPAP treatment reduce cardiovascular risk patient dyslipidemia mild-moderate OSA . DESIGN Randomized , parallel group , non-blind , control clinical trial conventional treatment . STUDY POPULATION 35-75 year old subject , diagnose dyslipidemia last six month stable treatment last month diet , cholesterol lower drug , cholesterol LDL level &gt; 100 mg / dl last two successive visit clinic . Sample size . 38 patient complete test treatment arm . TREATMENT Patients randomize one follow treatment arm form : 1. hygiene dietary recommendation . 2. lifestyle intervention ( strict promotion daily physical activity dietary control ) . 3 . Treatment positive airway pressure ( CPAP ) . ENDPOINTS : Efficacy endpoint . - Primary endpoint : LDL-cholesterol . - Total cholesterol , HDL-cholesterol , triglycerides C-reactive protein high sensitivity ( hsCRP ) . - Systemic Biomarkers : inflammatory ( IL-6 , IL-8 tumor necrosis factor ( TNF ) -α ) , oxidative stress ( 8-isoprostane ) , endothelial damage ( endothelin , vascular cell adhesion molecule 1 ( VCAM-1 ) Intercellular Adhesion Molecule 1 ( ICAM-1 ) ) , sympathetic activity ( neuropeptide Y ) appetite-regulating hormone ( leptin , orexin A / hypocretin-1 ghrelin ) . - Fasting glucose , glycated hemoglobin ( HbA1c ) , fast insulin Homeostasis Model Assessment ( HOMA ) index quantitative insulin sensitivity check index ( QUICKI ) , thyroid-stimulating hormone ( TSH ) . - Clinical questionnaire : short-form ( SF ) -12 , EuroQoL , Functional Outcomes Sleep Questionnaire ( FOSQ ) International physical activity questionnaire ( IPAQ ) . Security endpoint . - Notification clinical adverse event . - Compliance CPAP ( average hour use per day ) . - Epworth Sleepiness Questionnaire . - Development cardiovascular event .</brief_summary>
	<brief_title>Effect Nasal CPAP Lipid Profile Patients With Dyslipidaemia Sleep Apnea</brief_title>
	<detailed_description>OBJECTIVES Main objective : To assess six month treatment CPAP , associate conventional treatment , improve lipid profile patient dyslipidemia mild-moderate apnea-hypopnea syndrome ( OSA ) . Secondary objective : - Determine additional effect CPAP insulin resistance dyslipidemia patient mild-moderate OSA . - Assess impact CPAP treatment reduce cardiovascular risk patient dyslipidemia mild-moderate OSA . - Analyze impact supplemental CPAP treatment glycemic control concentration hsCRP patient dyslipidemia mild-moderate OSA . - Establish impact supplemental CPAP treatment quality life relate health patient dyslipidemia mild-moderate OSA . - Evaluate effect CPAP inflammatory cytokine , oxidative stress biomarkers , sympathetic tone regulate hormone intake patient dyslipidemia mild-moderate OSA . - Correlate CPAP induce change lipid level change produce basal inflammatory response , oxidative stress , sympathetic activity intake regulate hormone . - Compare effect CPAP promotion daily physical activity lipid profile patient dyslipidemia mild-moderate OSA . - Identify subgroup patient uncontrolled dyslipidemia mild-moderate OSA wich six month treatment CPAP achieve pronounce reduction blood lipid . DESIGN Randomized , parallel group , non-blind , control clinical trial conventional treatment . STUDY POPULATION 35-75 year old subject , diagnose dyslipidemia last six month stable treatment last month diet , cholesterol lower drug , cholesterol LDL level &gt; 100 mg / dl last two successive visit clinic . Sample size . 38 patient complete test treatment arm . TREATMENT Patients randomize one follow treatment arm form : 1. hygiene dietary recommendation . 2. lifestyle intervention ( strict promotion daily physical activity dietary control ) . 3 . Treatment positive airway pressure ( CPAP ) . ENDPOINTS Efficacy endpoint . - Primary endpoint : LDL-cholesterol . - Total cholesterol , HDL-cholesterol , triglycerides C-reactive protein high sensitivity ( hsCRP ) . - Systemic Biomarkers : inflammatory ( IL-6 , IL-8 TNF-α ) , oxidative stress ( 8-isoprostane ) , endothelial damage ( endothelin , VCAM-1 ICAM-1 ) , sympathetic activity ( neuropeptide Y ) appetite-regulating hormone ( leptin , orexin A / hypocretin-1 ghrelin ) . - Fasting glucose , glycated hemoglobin ( HbA1c ) , fast insulin HOMA QUICKI index , TSH . - Clinical questionnaire : SF-12 , EuroQoL , FOSQ IPAQ . Security endpoint . - Notification clinical adverse event . - Compliance CPAP ( average hour use per day ) . - Epworth Sleepiness Questionnaire . - Development cardiovascular event . STATISTICAL PROCEDURES Data express mean ± standard deviation , median ( interquartile range ) percent , depend type distribution . For comparison group , t-Student test , Mann-Whitney U-test chi-square test use , appropriate . The relationship variable analyze Pearson correlation multiple linear regression . The treatment effect evaluate analysis variance repeat measure post-hoc multiple comparison , use Bonferroni test . A model multiple logistic regression apply determine variable associate treatment response . P value consider statistically significant &lt; 0.05 .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Diagnosis dyslipidemia : The existence previous clinical diagnostic dyslipidemia associate lipidlowering therapy . It also consider patient altered analytical , use follow cutoff : total cholesterol ≥ 200 mg / dl , triglycerides ≥ 180 mg / dl , HDLcholesterol ≤ 40 mg / dl LDLcholesterol ≥ 150 mg / dl . Lipidlowering treatment diet , stable last month . A concentration LDLcholesterol 100 mg / dl , month prior inclusion . An apneahypopnea index 530 h1 Apneahypopnea index less 5 h1 great 30 h1 . Predominance central apnea hypopnea , define 25 % respiratory event . Professional driver , risk profession respiratory failure ( accord criterion clinical pathway diagnosis treatment sleepdisordered breathing ) . Very excessive daytime sleepiness ( Epworth Sleepiness Scale &gt; 18 ) . Morbid obesity ( BMI &gt; 40 kg / m2 ) . Prior treatment CPAP .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>